One assay to test them all: Multiplex assays for expansion of respiratory virus surveillance

Frontiers in Medicine

Medicine

Claude Flamand¹  Jelena D. M. Feenstra²  Obiageli Okafor²  Manoj Gandhi²  Camilla Ulekleiv²  Lomor Kruy³  Leangyi Heng³  Seangmai Keo³  Narjis Boukli³  Kim Lay Chea³  Panha Chhim³  Erik A. Karlsson³  Kimhoung Sour³  Viseth Srey Horm³  Heidi Auerswald³  Bunthea Chhor³  Sophea In³ 

[1] Epidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia;Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, CNRS, Paris, France;Thermo Fisher Scientific, South San Francisco CA, United States;Virology Unit, National Influenza Center, WHO H5 Regional Reference Laboratory, World Health Organization COVID-19 Global Referral Laboratory, Institut Pasteur du Cambodge, Phnom Penh, Cambodia;

关键词: SARS-CoV-2;    influenza;    respiratory syncytial virus;    COVID-19;    multiplex assay;    diagnostic test;    surveillance;   

DOI  :  10.3389/fmed.2023.1161268

 received in 2023-02-08, accepted in 2023-03-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

Molecular multiplex assays (MPAs) for simultaneous detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza and respiratory syncytial virus (RSV) in a single RT-PCR reaction reduce time and increase efficiency to identify multiple pathogens with overlapping clinical presentation but different treatments or public health implications. Clinical performance of XpertXpress® SARS-CoV-2/Flu/RSV (Cepheid, GX), TaqPath™ COVID−19, FluA/B, RSV Combo kit (Thermo Fisher Scientific, TP), and PowerChek™ SARS-CoV-2/Influenza A&B/RSV Multiplex RT-PCR kit II (KogeneBiotech, PC) was compared to individual Standards of Care (SoC). Thirteen isolates of SARS-CoV-2, human seasonal influenza, and avian influenza served to assess limit of detection (LoD). Then, positive and negative residual nasopharyngeal specimens, collected under public health surveillance and pandemic response served for evaluation. Subsequently, comparison of effectiveness was assessed. The three MPAs confidently detect all lineages of SARS-CoV-2 and influenza viruses. MPA-LoDs vary from 1 to 2 Log10 differences from SoC depending on assay and strain. Clinical evaluation resulted in overall agreement between 97 and 100%, demonstrating a high accuracy to detect all targets. Existing differences in costs, testing burden and implementation constraints influence the choice in primary or community settings. TP, PC and GX, reliably detect SARS-CoV-2, influenza and RSV simultaneously, with reduced time-to-results and simplified workflows. MPAs have the potential to enhance diagnostics, surveillance system, and epidemic response to drive policy on prevention and control of viral respiratory infections.

【 授权许可】

Unknown   
Copyright © 2023 Boukli, Flamand, Chea, Heng, Keo, Sour, In, Chhim, Chhor, Kruy, Feenstra, Gandhi, Okafor, Ulekleiv, Auerswald, Horm and Karlsson.